Company Monitoring Page for Vivus

latest headlines for company on cafepharma

Vivus announces journal publication of Qsymia study results in type 2 diabetes
Seeking Alpha
Mon, 10/6/14 - 11:05 am
Tags:
Vivus, Qsymia, type 2 diabetes
Faster-acting erectile dysfunction drug gets FDA approval
Yahoo/Reuters
Thu, 09/18/14 - 09:13 am
Tags:
FDA, erectile dysfunction, Vivus, Auxilium, Stendra
Vivus acquires patent rights to Qsymia ingredient
Yahoo/AP
Mon, 08/25/14 - 09:54 am
Tags:
Vivus, patents, Qsymia, Janssen, JNJ
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales
Yahoo/Zacks.com
Fri, 08/8/14 - 11:40 am
Tags:
Vivus, earnings
The Implications of Obesity as a Disability in Europe
Motley Fool
Sun, 07/20/14 - 09:10 am
Tags:
obesity, weight loss, Arena Pharmaceuticals, Belviq, Orexigen, Vivus, Eisai, Qsymia, NB32
Vivus hits Actavis with Qsymia patent-infringement lawsuit
Fierce Pharma
Fri, 06/13/14 - 06:46 pm
Tags:
patents, Vivus, Qsymia, Actavis, generics
Arena vs Vivus: Which Obesity Stock is a Buy? (video)
Motley Fool
Sat, 05/31/14 - 10:04 am
Tags:
Arena Pharmaceuticals, Vivus, obesity, weight loss, Belviq, Qsymia
A Vivus Buyout? Fat Chance And A Good Time To Short
Seeking Alpha
Fri, 05/30/14 - 01:01 pm
Tags:
Vivus, M&A
Today's Top Biotech Stocks to Watch: Intercept Pharmaceuticals and VIVUS
Motley Fool
Thu, 05/29/14 - 09:17 am
Tags:
Vivus, Intercept Pharmaceuticals, M&A, Aspen Investments, OCA
A Greek Lawyer Managing a Little-Known Investment Fund Wants to Buy Vivus for $640 Million
TheStreet.com
Wed, 05/28/14 - 11:39 am
Tags:
Vivus, M&A, Aspen Investments
Orexigen's Weight Loss Drug Will Be Approved Soon And Will Lead Market - Here Is Why
Seeking Alpha
Wed, 05/28/14 - 09:45 am
Tags:
obesity, Orexigen, FDA, Contrave, Vivus, Qsymia, Belviq, Arena Pharmaceuticals
The Future of Fat Fighting: Next-Gen Obesity Drugs
Motley Fool
Sun, 05/25/14 - 10:30 am
Tags:
obesity, weight loss, Zafgen, beloranid, Arena, Vivus, Qsymia, Belviq
1 Obesity Drug Stock the Market Got Completely Wrong (video)
Motley Fool
Sun, 05/18/14 - 10:13 am
Tags:
Vivus, Qsymia, weight loss, obesity
Vivus's diet pill faces generic threat from Actavis
Yahoo/Reuters
Fri, 05/9/14 - 10:34 am
Tags:
Vivus, generics, obesity, Qsymia, Actavis
Will Arena Seize An Opportunity?
Seeking Alpha
Tue, 05/6/14 - 04:46 pm
Tags:
Arena Pharmaceuticals, Vivus, Orexigen, Belviq, obesity, Qsymia
Vivus Earnings On Tap
Seeking Alpha
Mon, 05/5/14 - 04:59 pm
Tags:
earnings, Vivus
1 of These 3 Cratering Biotechs is a Buy
Motley Fool
Sun, 04/20/14 - 09:27 am
Tags:
Halozyme, Exelixis, Vivus
Vivus needs more than boardroom shuffling to keep up with Arena's Belviq
Fierce Pharma
Mon, 04/14/14 - 08:42 am
Tags:
Belviq, Vivus, obesity, Arena Pharmaceuticals, Qsymia
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
Motley Fool
Thu, 04/3/14 - 09:21 am
Tags:
Medicines Company, Omeros, OPKO Health, Vivus, OMS721, Qsymia, Fibrocaps
Can Arena and VIVUS Profit From Glaxo's Troubles?
Motley Fool
Mon, 03/31/14 - 10:36 pm
Tags:
Arena Pharmaceuticals, Vivus, GSK, Alli, tampering

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.